60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, routine-filing, corporate-reporting
TL;DR
60 Degrees Pharma filed a routine 8-K on Jan 28, 2025. No major news.
AI Summary
On January 28, 2025, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or transactions detailed in the provided text. The company is incorporated in Delaware and its principal executive office is located in Washington, D.C.
Why It Matters
This 8-K filing indicates routine corporate reporting, with no immediate material impact on the company's operations or stock price based on the information provided.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any significant new risks or material adverse events.
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Washington, D.C. (location) — Address of registrant's principal executive office
FAQ
What is the primary purpose of this 8-K filing for 60 Degrees Pharmaceuticals, Inc.?
The 8-K filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate reporting.
When was the earliest event reported in this filing?
The earliest event reported is January 28, 2025.
In which state is 60 Degrees Pharmaceuticals, Inc. incorporated?
The company is incorporated in Delaware.
What is the principal executive office address for 60 Degrees Pharmaceuticals, Inc.?
The principal executive office is located at 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036.
Does this filing disclose any specific new material events or transactions?
Based on the provided text, no specific new material events or transactions are detailed; it appears to be for routine reporting categories.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-28 16:05:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
Filing Documents
- ea0228966-8k_60degrees.htm (8-K) — 30KB
- ea022896601ex99-1_60degree.htm (EX-99.1) — 27KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-007529.txt ( ) — 286KB
- sxtp-20250128.xsd (EX-101.SCH) — 4KB
- sxtp-20250128_def.xml (EX-101.DEF) — 26KB
- sxtp-20250128_lab.xml (EX-101.LAB) — 36KB
- sxtp-20250128_pre.xml (EX-101.PRE) — 25KB
- ea0228966-8k_60degrees_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On January 28, 2025, 60 Degrees Pharmaceuticals, Inc. (the "Company") issued a press release announcing the approval of an Investigational Review Board (IRB) sanctioned Phase II clinical study. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release dated January 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: January 28, 2025 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 2